Actualités

But is that performance sustainable?

The sticker shock on the pharma giant's shares fades once you look at what investors are paying for the earnings expected just two years from now.

The telehealth provider shared patient health information with Snap and Meta, a federal complaint says.

Novo Nordisk's Q2 results are set to spotlight Ozempic and Wegovy sales as oral launches and label expansions drive growth amid mounting competitive pressure.

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Lilly's pipeline is on track to pick up a handful of interesting new programs.

Will this pharma company become a new leader in the weight loss market?

Johnson & Johnson's revenue has grown modestly while Eli Lilly's revenue has nearly doubled in two years, narrowing a once-wide gap.

Cathie Wood is loading up on shares of a biotech that could be one of the first entrants to the psychedelics market.

Eli Lilly (LLY) closed the most recent trading day at $1, moving +2.09% from the previous trading session.

Johnson & Johnson stock's oncology engine and its steady guidance raises were on the record quarters before the price moved.

One of the market's strongest health care performers barely moves with the index you already own, and that gap is the whole point.

Incyte tops Q2 earnings and revenue estimates as Jakafi and Opzelura sales surged, prompting the company to raise its 2026 revenue outlook.

The company isn't resting on its laurels.

Eli Lilly's expanding oncology and newer medicine portfolio is set to play a pivotal role in its Q2 earnings alongside its blockbuster GLP-1 franchise.

A quality compounder is a business that not only sports durable competitive advantages but also builds on its success by consistently reinvesting its profits at high returns.

The drugmaker's rapid stock gains have led to a premium valuation, forcing investors to question its capacity for future growth.

UNH's post-earnings pullback follows a 52-week high, as stronger guidance offsets Medicaid pressures and spotlights healthcare ETFs with sizable exposure.

Analysts have been lifting Eli Lilly price targets, with recent valuation work for the stock pointing to fair value of US$1,270.37 compared with the prior US$1,243.43 anchor. The shift lines up with a more constructive Wall Street stance as firms reassess the obesity and diabetes portfolio, retatrutide data, and Q2 earnings setup, with bullish targets clustering between roughly US$1,232 and US$1,600. Ahead, you will see how this evolving narrative, both bullish and cautious, can shape how you...

Here is a way to get paid a significant income stream today from Eli Lilly stock, which you keep no matter what, while setting a price far below current levels where you would be willing to buy.

The chief investment strategist at Concurrent Asset Management shares her top investment picks right now.

The company that used to reassure you with its sheer breadth now leads with a push to dominate oncology, and a holder who bought a diversified compounder should notice the bet has changed shape.

Eli Lilly (LLY) stock has turned into one of the best comeback trades of 2026. Shares closed at $1,196.03 on July 24, up nearly 11% year to date after a rough start dragged the stock below $900 in the spring. Lilly shares have climbed about 39% since the company's first-quarter report, according to ...

Management's plain health care label has slipped out of the lead, and the business now on a separation clock is the one that finally started working.

As AI-related stocks weaken, investors are rotating into other sectors, such as energy and health care.

Novo Nordisk A/S (NYSE:NVO) was at the center of media coverage as it sued rival weight loss drug manufacturer Eli Lilly on Tuesday. The firm claimed that Lilly had run misleading advertisements about its weight loss drug when it came to touting their superior performance over Novo Nordisk A/S (NYSE:NVO)’s products. It claimed that Lilly […]

<body><p>STORY: U.S. stocks ended mixed on Friday, with the Dow gaining just under half a percent, the S&P 500 virtually flat and the tech-heavy Nasdaq sliding nearly two-thirds of a percent.</p><p>The S&P 500 technology index underperformed the broader market as chip stocks fell, with Intel dropping nearly 8% despite forecasting quarterly profit and revenue above Wall Street estimates.</p><p>Enthusiasm for the AI trade weakened after Alphabet's announcement earlier this week of a plan to hike capital spending even as it burns cash.</p><p>Richard Reyle, chief investment officer at Questar Capital Partners, said that as a result investors are rotating into what he called "safer parts of the market."</p><p>"Pharmaceuticals have been flying, and that's been, I think, where we see the rotation of the market right now. [FLASH] You look at the iShares, pharmaceutical fund, it's big components that are J&J and Eli Lilly, they're at all-time highs. And they're still relatively not super expensive stocks. So I think that's a place that can be bought and held. And of course, energy. Exxon's going to announce earnings next week. I bet they're going to be a blockbuster and they're going to continue to be because they make money at $60 a barrel. At $100 a barrel, forget about it. They do very well."</p><p>The S&P 500 real estate sector also outperformed during the session. Its leading gainer was Digital Realty Trust, which rallied 11% after it raised its full-year forecast for funds from operations.</p><p>Among other gainers, shares of SLB climbed 11% after the oilfield services firm beat expectations for second-quarter profit.</p><p>Investors now turn their attention to quarterly results next week from Magnificent 7 megacaps Microsoft, Amazon, Meta and Apple.</p></body>

Healthcare stocks rose late Friday afternoon, with the NYSE Healthcare Index up 0.6% and the State S

Gene-editing biotech debuts at $25, backed by Sanofi and Eli Lilly, with a roughly $440.3 million valuation.

Eli Lilly just won FDA clearance for an oral GLP-1 that targets over one billion potential patients worldwide, and the stock has barely moved. Here is whether that disconnect signals a buying opportunity or a trap.